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In the course of embryonic
development, during some normal
physiological processes in the adult,
such as the female reproductive cycle,
and also in a variety of pathologies,
including tumour growth, new blood
vessels develop from the pre-existing
vascular network through endothelial
cell sprouting, proliferation and fusion
- a process termed angiogenesis (Risau,
1997). Blocking tumour angiogenesis
has become a promising approach in
managing cancer: in recent years, a
large number of anti-angiogenic drugs
and recombinant proteins have entered
clinical trials, and some are already in
the ﬁnal phase of testing (see
http://cancertrials.nci.nih.gov). 
Research into tumour angiogenesis was
kick-started by the realisation that
tumours are not able to grow beyond a
size of 1-2 mm3 without ﬁrst recruiting
their own vascular supply to deliver
oxygen and nutrients (Folkman, 1971).
A wide variety of pro-angiogenic
molecules were subsequently found to
be released from cancerous cells, most
importantly vascular endothelial growth
factor (VEGF) and basic ﬁbroblast
growth factor (bFGF; step I; Kerbel,
2000). 
Generally, angiogenesis can be inhibited
at any of a number of key steps in the
endothelial growth cycle, in which a
quiescent vessel becomes an actively
growing and invading endothelial tube
(Kerbel, 2000). The activation of resting
vessels by tumour-derived angiogenic
factors such as VEGF can be blocked by,
for example, neutralising antibodies or
compounds that impair downstream
signalling (inhibition of step I).
Degradation of the extracellular matrix
by activated endothelial cells can also be
prevented, which suppresses sprouting
and invasion of growing capillaries into
their surrounds (inhibition of step II).
Alternatively, endothelial cell
proliferation can be inhibited by agents
that block signalling within the cell and
arrest its division cycle (inhibition of
step III) or by agents that prevent the
maturation of nascent endothelial cells
into functional tubes (inhibition of step
IV). Finally, endothelial cells can be
forced to apoptose, which destroys
existing tumour vessels and thereby
impairs survival of large tumour masses
and metastasis through the vascular
route (inhibition of step V). Excitingly,
some inhibitors target the tumour
vasculature at more than one of these
steps, which should increase their
efficiency. For example, in addition to
stimulating resting vessels, VEGF
promotes both proliferation and survival
of endothelial cells, and antibodies
against this endothelial cell-speciﬁc
growth factor might therefore target both
quiescent and actively cycling
endothelial cells.
Hijacking naturally occurring inhibitors
of angiogenesis to block tumour
vascularisation might minimise side
effects commonly associated with the
use of artiﬁcial compounds in cancer
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therapy. Experimental tests on tumour
bearing animals are indeed promising:
recombinant angiogenic inhibitors such
as endostatin can shrink tumours to a
bearable size and might be used to keep
them small indeﬁnitely, since resistance
does not build up to these agents, and
their toxicity is low. If these are used in
combination with more traditional
cancer drugs, which target tumour cells
directly, cancers that are currently
incurable might at least become
manageable.
Abbreviations/deﬁnitions: Ang1/2, angiopoetin 1/2
- ligand for Tie-2 receptor; angiostatin - kringle-
domain containing fragment of plasminogen (a
protein involved in the blood clotting/ﬁbrinolytic
pathway); anti-thrombin - serpin-family member
involved in the blood clotting/ﬁbrinolytic pathway;
endostatin - fragment of type XVIII collagen in the
extracellular matrix; bFGF, basic ﬁbroblast growth
factor; FGFR, FGF receptor; FLK-1, fms-like
kinase 1; VEGF receptor (also known as VEGFR2
or KDR); HSPG, heparan sulphate proteoglycan in
the extracellular matrix; Meth1/2, protein
containing metalloproteases and thrombospondin
domains; PF4, fragment of platelet factor 4; NRP1,
neuropilin 1 - FLK-1 co-receptor; sNRP1, secreted
fragment of neuropilin 1; Tie-2, angiopoetin
receptor (also known as Tek); thrombin - protein
in the blood clotting/ﬁbrinolytic pathway that
upregulates VEGF receptors; TSP1,
thrombospondin 1 - extracellular matrix protein;
VEGF, vascular endothelial growth factor;
vasostatin - fragment of calreticulin (a protein in
the endoplasmic reticulum involved in calcium
signalling).
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